TP53 Mutations in Canine Brain Tumors

Veterinary Pathology

Volumn 49, Issue 5, 2012, Pages 796-801

  York, D ^a   Higgins, R J ^a   LeCouteur, R A ^a   Wolfe, A N ^a   Grahn, R ^b   Olby, N ^c   Campbell, M ^a   Dickinson, P J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

cancer genes; dog; gDNA; nervous system; oncology; polymerase chain reaction; sequencing

Indexed keywords

COMPLEMENTARY DNA; DNA; RNA;

ANIMAL; ANIMAL DISEASE; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CHEMISTRY; DNA SEQUENCE; DOG; DOG DISEASE; EXON; FEMALE; GENE FREQUENCY; GENETICS; MALE; MUTATION; TUMOR SUPPRESSOR GENE;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; DNA, COMPLEMENTARY; DNA, NEOPLASM; DOG DISEASES; DOGS; EXONS; FEMALE; GENE FREQUENCY; GENES, P53; MALE; MUTATION; RNA, NEOPLASM; SEQUENCE ANALYSIS, DNA;

CANIS FAMILIARIS;

EID: 84866405026     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985811424734     Document Type: Article

References (46)

1. Amatya VJ,Takeshima Y,Inai K.Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation.Mod Pathol. 2004;17:705-710.
2. Berens ME,Bjotvedt G,Levesque DC, et al.Tumorigenic, invasive, karyotypic, and immunocytochemical characteristics of clonal cell lines derived from a spontaneous canine anaplastic astrocytoma.In Vitro Cell Dev Biol Anim. 1993;29:310-318.
3. Biernat W,Kleihues P,Yonekawa Y, et al.Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.J Neuropathol Exp Neurol. 1997;56:180-185.
4. Bogler O,Huang HJ,Kleihues P, et al.The p53 gene and its role in human brain tumors.Glia. 1995;15:308-327.
5. Chou MY,Underwood JG,Nikolic J, et al.Multisite RNA binding and release of polypyrimidine tract binding protein during the regulation of c-src neural-specific splicing.Mol Cell. 2000;5:949-957.
6. Chow LM,Endersby R,Zhu X, et al.Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.Cancer Cell. 2011;19:305-316.
7. Chu LL,Rutteman GR,Kong JM, et al.Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia.Breast Cancer Res Treat. 1998;50:11-25.
8. Dearth LR,Qian H,Wang T, et al.Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.Carcinogenesis. 2007;28:289-298.
9. Devilee P,Van Leeuwen IS,Voesten A, et al.The canine p53 gene is subject to somatic mutations in thypoid carcinoma.Anticancer Res. 1994;14:2039-2046.
10. Hagel C,Krog B,Laas R, et al.Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.J Exp Clin Cancer Res. 1999;18:305-309.
11. Hainaut P,Hollstein M.p53 and human cancer: the first ten thousand mutations.Adv Cancer Res. 2000;77:81-137.
12. Harvey M,Vogel H,Morris D, et al.A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.Nat Genet. 1995;9:305-311.
13. Jeon YK,Park K,Park CK, et al.Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.Neuropathology. 2007;27:10-20.
14. Kabat JL,Barberan-Soler S,McKenna P, et al.Intronic alternative splicing regulators identified by comparative genomics in nematodes.PLoS Comput Biol. 2006;2:e86.
15. Kato S,Han SY,Liu W, et al.Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.Proc Natl Acad Sci U S A. 2003;100:8424-8429.
16. Kleihues P,Ohgaki H,Eibl RH, et al.Type and frequency of p53 mutations in tumors of the nervous system and its coverings.Recent Results Cancer Res. 1994;135:25-31.
17. Lane DP,Cheok CF,Lain S.p53-based cancer therapy.Cold Spring Harb Perspect Biol. 2010;2:a001222.
18. Lehman TA,Haffty BG,Carbone CJ, et al.Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer.Cancer Res. 2000;60:1062-1069.
19. Louis DN,Ohgaki H,Wiestler OD, et al.The 2007 WHO classification of tumours of the central nervous system.Acta Neuropathol (Berl). 2007;114:97-109.
20. Marsh A,Spurdle AB,Turner BC, et al.The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia.Breast Cancer Res. 2001;3:346-349.
21. Mashiyama S,Murakami Y,Yoshimoto T, et al.Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.Oncogene. 1991;6:1313-1318.
22. Mayr B,Resch S,Hepperle S, et al.Comparative studies in the promoter and exon 1 regions of tumour suppressor p53 in several mammalian species: absence of mutations in a panel of spontaneous domestic animal tumours.J Vet Med A Physiol Pathol Clin Med. 2000;47:593-597.
23. Mayr B,Schellander K,Schleger W, et al.Sequence of an exon of the canine p53 gene: mutation in a papilloma.Br Vet J. 1994;150:81-84.
24. Mendoza S,Konishi T,Dernell WS, et al.Status of the p53, Rb and MDM2 genes in canine osteosarcoma.Anticancer Res. 1998;18:4449-4453.
25. Milner J,Medcalf EA.Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.Cell. 1991;65:765-774.
26. Moll UM,LaQuaglia M,Benard J, et al.Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.Proc Natl Acad Sci U S A. 1995;92:4407-4411.
27. Nasir L,Rutteman GR,Reid SW, et al.Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas.Cancer Lett. 2001;174:83-89.
28. Ohgaki H,Eibl RH,Wiestler OD, et al.p53 mutations in nonastrocytic human brain tumors.Cancer Res. 1991;51:6202-6205.
29. Oliner JD,Kinzler KW,Meltzer PS, et al.Amplification of a gene encoding a p53-associated protein in human sarcomas.Nature. 1992;358:80-83.
30. Petitjean A,Mathe E,Kato S, et al.Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.Hum Mutat. 2007;28:622-629.
31. Rampino N,Yamamoto H,Ionov Y, et al.Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.Science. 1997;275:967-969.
32. Reifenberger G,Liu L,Ichimura K, et al.Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.Cancer Res. 1993;53:2736-2739.
33. Reifenberger J,Ring GU,Gies U, et al.Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.J Neuropathol Exp Neurol. 1996;55:822-831.
34. Setoguchi A,Sakai T,Okuda M, et al.Aberrations of the p53 tumor suppressor gene in various tumors in dogs.Am J Vet Res. 2001;62:433-439.
35. Sidransky D,Mikkelsen T,Schwechheimer K, et al.Clonal expansion of p53 mutant cells is associated with brain tumour progression.Nature. 1992;355:846-847.
36. Stoica G,Kim HT,Hall DG, et al.Morphology, immunohistochemistry, and genetic alterations in dog astrocytomas.Vet Pathol. 2004;41:10-19.
37. Van Leeuwen IS,Hellmen E,Cornelisse CJ, et al.P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.Anticancer Res. 1996;16:3737-3744.
38. van Oijen MG,Slootweg PJ.Gain-of-function mutations in the tumor suppressor gene p53.Clin Cancer Res. 2000;6:2138-2145.
39. Veldhoen N,Stewart J,Brown R, et al.Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog.Oncogene. 1998;16:249-255.
40. von Deimling A,Eibl RH.Ohgaki H,et al.p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.Cancer Res. 1992;52:2987-2990.
41. von Deimling A,von Ammon K,Schoenfeld D, et al.Subsets of glioblastoma multiforme defined by molecular genetic analysis.Brain Pathol. 1993;3:19-26.
42. Wakui S,Muto T,Yokoo K, et al.Prognostic status of p53 gene mutation in canine mammary carcinoma.Anticancer Res. 2001;21:611-616.
43. Watanabe K,Sato K,Biernat W, et al.Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.Clin Cancer Res. 1997;3:523-530.
44. Watanabe K,Tachibana O,Sata K, et al.Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.Brain Pathol. 1996;6:217-223.
45. Wu JK,Ye Z,Darras BT.Frequency of p53 tumor suppressor gene mutations in human primary brain tumors.Neurosurgery. 1993;33:824-830.
46. Zhang XH,Leslie CS,Chasin LA.Dichotomous splicing signals in exon flanks.Genome Res. 2005;15:768-779.